Lucid Diligence Brief: Sprint Bioscience sells TREX1 program to Gilead
Lucid Diligence Brief: Sprint Bioscience sells TREX1 program to Gilead…
Lucid Diligence Brief: Vaximm VXM01 License Term Sheet with BCM Europe
Lucid Diligence Brief: Vaximm VXM01 License Term Sheet with BCM Europe…
Lucid Diligence Brief: Aspen Neuroscience $115M Series C
Lucid Diligence Brief: Aspen Neuroscience $115M Series C Professional audiences…
Lucid Diligence Brief: Neurogen Biomarking and Tasso partnership for at-home Alzheimer’s blood collection
Lucid Diligence Brief: Neurogen Biomarking and Tasso partnership for at-home…
Lucid Diligence Brief: WellBeam $10M Series A
Lucid Diligence Brief: WellBeam $10M Series A Professional audiences only. Not…
Lucid Diligence Brief: Abbott to acquire Exact Sciences
Lucid Diligence Brief: Abbott to acquire Exact Sciences Professional audiences…
Lucid Diligence Brief: Philips and Cortechs.ai quantitative neuroimaging partnership
Lucid Diligence Brief: Philips and Cortechs.ai quantitative neuroimaging…
Lucid Diligence Brief: Tempest Therapeutics and Factor Bioscience dual-CAR T deal
Lucid Diligence Brief: Tempest Therapeutics and Factor Bioscience dual-CAR T…
Lucid Diligence Brief: Avanzanite Bioscience €32m Series A
Lucid Diligence Brief: Avanzanite Bioscience €32m Series A Professional…
Lucid Diligence Brief: Johnson & Johnson acquires Halda Therapeutics
Lucid Diligence Brief: Johnson & Johnson acquires Halda Therapeutics…
Lucid Diligence Brief: ABL Bio and Eli Lilly Grabody-B license deal
Lucid Diligence Brief: ABL Bio and Eli Lilly Grabody-B license deal…
Lucid Diligence Brief: Merck to acquire Cidara Therapeutics
Lucid Diligence Brief: Merck to acquire Cidara Therapeutics Professional…